Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Cancer Res. 2015 May 15;75(14):2800–2810. doi: 10.1158/0008-5472.CAN-14-3041

Figure 2. FAP-CAR T cells confer anti-tumor activity in desmoplastic human lung cancer in immunodeficient hosts.

Figure 2

(A) NSG mice bearing established A549 tumors received FAP-CAR human T cells i.v. (B) To test target-specificity of FAP-CAR T cells, NSG FAP-null tumor-bearing mice were injected i.v. with FAP-CAR human T cells. (C) NSG mice bearing I45 tumors were injected i.v. with FAP-CAR human T cells. The black arrow indicates the time of T cell transfer (n=5 per group). A549 tumors were harvested 8 days post-adoptive T cell transfer. Tumor sections were stained with antibodies against human-specific ki-67 (D) and cleaved caspase-3 (E) (n=3 per group). * Denotes statistical significance between untreated and FAP-CAR T cell-treated samples, p value < 0.01. Scale: 100 μm.

HHS Vulnerability Disclosure